Search
Contact Us
LinkedIn
Twitter
About Stoke
Overview
Leadership
Founders
Corporate Responsibility
Scientific Platform
Overview
TANGO
Publications
Disease Areas
Overview
Dravet Syndrome
ADOA
SYNGAP1
Pipeline
Patients & Families
Overview
Clinical Studies
Expanded Access Policy
Educational Resources
Careers & Culture
Overview
Job Opportunities
Diversity, Inclusion & Belonging
Investors & News
Overview
Media Room
Press Releases
Events & Presentations
Financials & SEC Filings
Stock Information
Analyst Coverage
Governance
Settlement Information
Menu
Search
About Stoke
Overview
Leadership
Founders
Corporate Responsibility
Scientific Platform
Overview
TANGO
Publications
Disease Areas
Overview
Dravet Syndrome
ADOA
SYNGAP1
Pipeline
Patients & Families
Overview
Clinical Studies
Expanded Access Policy
Educational Resources
Careers & Culture
Overview
Job Opportunities
Diversity, Inclusion & Belonging
Investors & News
Overview
Media Room
Press Releases
Events & Presentations
Financials & SEC Filings
Stock Information
Analyst Coverage
Governance
Settlement Information
Contact Us
Home
Scientific Platform
Publications
OSPREY: A Phase 1, Open-Label Study Evaluating the Safety and Tolerability of the Antisense Oligonucleotide STK‐002 in Patients with OPA1 Autosomal Dominant Optic Atrophy
OSPREY: A Phase 1, Open-Label Study Evaluating the Safety and Tolerability of the Antisense Oligonucleotide STK‐002 in Patients with OPA1 Autosomal Dominant Optic Atrophy
EUNOS 2026
June 5, 2026
